Journal article
Cell-bound complement activation products associate with lupus severity in SLE
Lupus science & medicine, v 7(1), e000377
05 May 2020
PMID: 32371480
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
ObjectivesTo evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4.MethodsAll subjects (n=495) fulfilled the American College of Rheumatology (ACR) classification criteria for SLE. Abnormal CB-CAPs (erythrocyte-bound C4d or B-lymphocyte-bound C4d levels >99th percentile of healthy) and complement proteins C3 and C4 were determined using flow cytometry and turbidimetry, respectively. Lupus severity was estimated using the Lupus Severity Index (LSI). Statistical analysis consisted of multivariable linear regression and groups comparisons.ResultsAbnormal CB-CAPs were more prevalent than low complement values irrespective of LSI levels (62% vs 38%, respectively, p<0.0001). LSI was low (median 5.44, IQR: 4.77–6.93) in patients with no complement abnormality, intermediate in patients with abnormal CB-CAPs (median 6.09, IQR: 5.31–8.20) and high in the group presenting with both abnormal CB-CAPs and low C3 and/or C4 (median 7.85, IQR: 5.51–8.37). Odds of immunosuppressant use was higher in subjects with LSI ≥5.95 compared with subjects with LSI <5.95 (1.60 vs 0.53, p<0.0001 for both). Multivariable regression analysis revealed that higher LSI scores associated with abnormal CB-CAPs—but not low C3/C4—after adjusting for younger age, race and longer disease duration (p=0.0001), which were also independent predictors of disease severity (global R2=0.145).ConclusionAbnormalities in complement activation as measured by CB-CAPs are associated with increased LSI.
Metrics
Details
- Title
- Cell-bound complement activation products associate with lupus severity in SLE
- Creators
- Cristina Arriens - Oklahoma Medical Research FoundationRoberta Vezza Alexander - Exagen Inc, Vista, California, USASonali Narain - Northwell HealthAmit Saxena - New York UniversityChristopher E Collins - MedStar Washington Hospital CenterDaniel J Wallace - Attune Health, Beverly Hills, California, USAElena Massarotti - Harvard UniversityJohn Conklin - Exagen Inc, Vista, California, USAKenneth C Kalunian - University of California SystemChaim Putterman - Albert Einstein College of MedicineRosalind Ramsey-Goldman - Northwestern UniversityJill P Buyon - New York UniversityAnca Askanase - Columbia University Irving Medical CenterRichard A Furie - Northwell HealthJudith A James - Oklahoma Medical Research FoundationGhalib A Bello - Oklahoma Medical Research FoundationSusan Manzi - Allegheny Health NetworkJoseph Ahearn - Allegheny Health NetworkTyler O'Malley - Exagen Inc, Vista, California, USAArthur Weinstein - Exagen Inc, Vista, California, USAThierry Dervieux - Exagen Inc, Vista, California, USA
- Publication Details
- Lupus science & medicine, v 7(1), e000377
- Publisher
- British Medical Journal (BMJ)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate); General Internal Medicine
- Web of Science ID
- WOS:000568372200002
- Scopus ID
- 2-s2.0-85085334033
- Other Identifier
- 991021934011404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Rheumatology